medigraphic.com
Revista Médica Sinergia

2022, Número 12

<< Anterior Siguiente >>

Revista Médica Sinergia 2022; 7 (12)


Neuro-Behçet: diagnóstico diferencial de enfermedades desmielinizantes

Vásquez CJM, Solera VA, Madrigal CJP, Rivera SN

Idioma: Español
Referencias bibliográficas: 20
Paginas:
Archivo PDF: 206.93 Kb.


RESUMEN

La enfermedad de Behçet (EB) es una vasculitis inflamatoria multisistémica de etiología incierta e infrecuente, clasificada como una enfermedad rara en Estados Unidos y países europeos. El síndrome de Neuro-Behçet (SNB) ocurre cuando se presenta compromiso neurológico en pacientes con EB, en los cuales se ha descartado otras etiologías neurológicas. El espectro de afectación neurológica en la EB es muy amplio, sin embargo, las manifestaciones clínicas y los hallazgos de neuroimagen guían hacia dos grandes grupos de SNB: parenquimatoso y no parenquimatoso. La EB se debe incluir en el diagnóstico diferencial de enfermedades inflamatorias, vasculares y desmielinizantes del SNC.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Caruso P, Moretti R. Focus on neuro-Behçet's disease: A review. Neurol India. Nov, 2018; 66(6):1619-1628. Doi: https://doi.org/10.4103/0028-3886.246252

  2. Houman MH, Bellakhal S, Salem TB, Hamzaoui A, Braham A, Lamloum M, et al. Characteristics of neurological manifestatios of Behçet's disease: a retrospective monocentric study in Tunisia. Clinical Neurology and Neurosurgery. Oct 2013;115(10):2015-2018. Doi: https://doi.org/10.1016/j.clineuro.2013.06.009

  3. Saip S, Akman G, Siva A. Handbook of Clinical Neurology, Chapter 10: Neuro Behcet syndrome. Elsevier 2014; 121.

  4. Cagri E, Sari A, Kilic L, Kalyoncu U, Kurne A, Oguz KK, Akif M, Ertenli I, Karadag O. Clinical features and disease course of neurological involvement in Behcet's disease: HUVAC experience. Multiple sclerosis and related disorders. Feb, 2020;38(1):1-7. Doi: https://doi.org/10.1016/j.msard.2019.101512

  5. Borhani A, Kardeh B, Banerjee S, Yadollahikhales G, Safari A, Ali M, Shapiro L. Neuro-Behcet's disease: An update on diagnosis, differential diagnoses, and Treatment. Multiple sclerosis and related disorders. Dec, 2020;39(1):1-15. Doi: https://doi.org/10.1016/j.msard.2019.101906

  6. López A, Parra C, Bellosta E, Cecilio A, Santos S. Manifestaciones neurológicas de la enfermedadde Behcet: descripción de un caso y revisión de la literatura. Reumatología clínica. Sep, 2019;15(5):36-38. Doi: https://doi.org/10.1016/j.reuma.2017.04.009

  7. Hayriye M, Aykut M, Yucesan C. Clinical characteristics and prognosis of Neuro-Behçet’s disease. Eur J Rheumatol. Dec, 2018;5(4):235-9. Doi: https://doi.org/10.5152/eurjrheum.2018.18033

  8. Siva A, Saip S. The spectrum of nervous system involvement in Behçet’s syndrome and its differential diagnosis. Journal of Neurology. Apr, 2009;256(4):513–529. Doi: https://doi.org/10.1007/s00415-009-0145-6

  9. Fountain E, Dhurandhar A. Neuro-Behçet’s Disease: An Unusual Cause of Headache. Journal of General Internal Medicine. Feb, 2014;29(6):956–960. Doi: https://doi.org/10.1007/s11606-014-2781-5

  10. Casanova I, De las Heras V, Parejo B, Di Capua D, Fuentes E, García R, Arroyo R. Neurobehçet disease: clinical and demographic characteristics European Journal of Neurology. Apr, 2012;19(9):1224–1227. Doi: https://doi.org/10.1111/j.1468-1331.2012.03706.x

  11. Saip S, Akman G, Siva A. Neuro-Behçet syndrome. Neurologic Aspects of Systemic Disease Part III. 2014:1703–1723. Doi: https://doi.org/10.1016/B978-0-7020-40887.00110-3

  12. Diri E, Espinoza LR. Neuro-behçet’s syndrome: Differential diagnosis and management. Curr Rheumatol Rep. Aug, 2006;8(4):317–322. Doi: https://doi.org/10.1007/s11926-006-0016-4

  13. Uygunoğlu U, Siva A. Behçet’s Syndrome and Nervous System Involvement. Curr Neurol and Neurosci Rep. May, 2018;18(7):35. Doi: https://doi.org/10.1007/s11910-018-0843-5

  14. Kalra S, Silman A, Akman-Demir G, Bohlega S, Borghani-Haghighi A, Constantinescu CS, Houman H, Mahr A, Salvarani C, Sfikakis PP, Siva A, Al-Araji A. Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendations. Journal of Neurology. Sep, 2014;261(9):1662–1676. Doi: https://doi.org/10.1007/s00415-013-7209-3

  15. Mohamed C, Najib K, Essaadouni L. Radiological findings in Behçet disease. Pan African Medical Journal. Jan, 2015;20(51). Doi: https://doi.org/10.11604/pamj.2015.20.51.5928

  16. Yin L, Riminton DS, Nguyen M, Barnett MH, Reddel SW, Hardy TA. The spectrum of immune-mediated and inflammatory lesions of the brainstem: Clues to diagnosis. Neurology. Aug,2019;93(9):390-405. Doi: https://doi.org/10.1212/WNL.0000000000008015

  17. Maggi P, Absinta M, Grammatico M, Vuolo L, Emmi G, Carlucci G, et al. Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Annals of Neurology. Jan, 2018; 83(2);283-294. Doi: https://doi.org/10.1002/ana.25146

  18. Saleh Z, Arayssi T. Update on the therapy of Behçet disease. Therapeutic Advances in Chronic Disease. May, 2014; 5(3): 112–134. Doi: https://doi.org/10.1177/2040622314523062

  19. Arida A, Fragiadaki K, Giavri E, Sfikakis P. Anti-TNF agents for Behcet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. Aug, 2011;41(1):61–70. Doi: https://doi.org/10.1016/j.semarthrit.2010.09.002

  20. Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, Chams-Davatchi C, Akhlaghi M, Faezi T, Naderi N. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). International Journal of Rheumatic Diseases. Aug, 2010;13(3):246–252. Doi: https://doi.org/10.1111/j.1756-185X.2010.01546.x




2020     |     www.medigraphic.com